Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
| ▸ | CTSG | P08311 | 1/20 | 0.39 |
| ▸ | CTRC | Q99895 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20960393 | 0.85 | CYP19A1 (0.50) | ADAM17CYP19A1 | |
| SCHEMBL19749316 | 0.82 | CYP19A1 (0.39) | HTTADAM17CYP19A1 | |
| SCHEMBL15474242 | 0.82 | CYP19A1 (0.53) | ALDH1A1CYP19A1 | |
| SCHEMBL25091333 | 0.80 | CYP19A1 (0.54) | ALDH1A1CYP19A1 | |
| SCHEMBL10794648 | 0.79 | CYP19A1 (0.55) | ALDH1A1CYP19A1 | |
| SCHEMBL21697502 | 0.79 | CYP19A1 (0.55) | ALDH1A1CYP19A1 | |
| SCHEMBL22593893 | 0.79 | CYP19A1 (0.55) | ALDH1A1CYP19A1 | |
| SCHEMBL22765385 | 0.78 | ADAM17 (0.35) | ADAM17CYP19A1 | |
| SCHEMBL25017812 | 0.78 | ADAM17 (0.35) | ADAM17CYP19A1 | |
| SCHEMBL23775260 | 0.76 | ADAM17 (0.44) | TSHRALDH1A1ADAM17 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12018093-B2 | Hemiasterlin derivatives and antibody-drug conjugates including same | Sumitomo Pharma Co., Ltd. (JP) | 2024-06-25 | — | — | US | disclosed |
| US-11795195-B2 | Antibody-drug conjugates including hemiasterlin derivative | Sumitomo Pharma Co., Ltd. (JP) | 2023-10-24 | — | — | US | disclosed |
| US-11779602-B2 | Methods of use for CAR T cells | ENDOCYTE, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11759480-B2 | Compositions and methods for CAR T cell therapy | ENDOCYTE, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-11717514-B2 | PSMA binding ligand-linker conjugates and methods for using | PURDUE RESEARCH FOUNDATION (US) | 2023-08-08 | — | — | US | disclosed |
| WO-2022256507-A1 | TREATMENT OF CANCER IN PATIENTS WITH SOLUBLE FR-ALPHA | IMMUNOGEN, INC. (US) | 2022-12-08 | — | — | WO | disclosed |
| EP-3901162-A1 | GLUCOCORTICOID RECEPTOR AGONIST AND IMMUNOCONJUGATES THEREOF | AbbVie Inc. (US) | 2021-10-27 | — | — | EP | disclosed |
| EP-3268050-B1 | PORE-FORMING PROTEIN CONJUGATE COMPOSITIONS AND METHODS | UNIV COLUMBIA (US) | 2021-07-14 | — | — | EP | disclosed |
| US-20210154311-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | ENDOCYTE INC (US) | 2021-05-27 | — | — | US | disclosed |
| US-20210077468-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION | 2021-03-18 | — | — | US | disclosed |
| US-8465724-B2 | Multi-drug ligand conjugates | ENDOCYTE, INC. (US) | 2013-06-18 | — | — | US | disclosed |
| US-20130116195-A1 | Binding ligand linked drug delivery conjugates of tubulysins | LEAMON CHRISTOPHER PAUL (US) | 2013-05-09 | — | — | US | disclosed |
| US-20120270791-A1 | Methods and Compositions for Treating and Diagnosing Kidney Disease | LEAMON CHRISTOPHER PAUL (US) | 2012-10-25 | — | — | US | disclosed |
| US-20120065149-A1 | Vitamin receptor binding drug delivery conjugates | VLAHOV IONTCHO R (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120022245-A1 | FOLATE TARGETING OF NUCLEOTIDES | PURDUE RESEARCH FOUNDATION (US) | 2012-01-26 | — | — | US | disclosed |
| US-20120003151-A1 | METHOD FOR EARLY IMAGING OF ATHEROSCLEROSIS | PURDUE RESEARCH FOUNDATION (US) | 2012-01-05 | — | — | US | disclosed |
| US-20100104626-A1 | METHODS AND COMPOSITIONS FOR TREATING AND DIAGNOSING KIDNEY DISEASE | ENDOCYTE, INC. (US) | 2010-04-29 | — | — | US | disclosed |
| US-20100048490-A1 | BINDING LIGAND LINKED DRUG DELIVERY CONJUGATES OF TUBULYSINS | ENDOCYTE, INC. | 2010-02-25 | — | — | US | disclosed |
| US-20080280937-A1 | Ligand Conjugates of Vinca Alkaloids, Analogs, and Derivatives | ENDOCYTE, INC. | 2008-11-13 | — | — | US | disclosed |
| US-20080248052-A1 | Vitamin receptor binding drug delivery conjugate | ENDOCYTE, INC. | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120003151-A1 | METHOD FOR EARLY IMAGING OF ATHEROSCLEROSIS | MSR1, VCAM1, CD14 | TSHR 3503/4885HTT 3830/4885F2 713/4885 |
| US-20120022245-A1 | FOLATE TARGETING OF NUCLEOTIDES | FOLR1, FOLR2, DHFR | TSHR 1536/4885HTT 2145/4885F2 3808/4885 |
| US-20130116195-A1 | Binding ligand linked drug delivery conjugates of tubulysins | TEK, TEKT1, CD2BP2 | TSHR 2447/4885HTT 639/4885F2 4254/4885 |
| US-20210077468-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | FOLH1, KLK3, PSMA1 | TSHR 3006/4885HTT 4374/4885F2 2448/4885 |
| US-20210154311-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | FOLH1, KLK3, CD47 | TSHR 3610/4885HTT 1461/4885F2 4489/4885 |
| US-20080248052-A1 | Vitamin receptor binding drug delivery conjugate | VDR, HCAR1, FOLR1 | TSHR 95/4885HTT 3729/4885F2 3461/4885 |
| US-11759480-B2 | Compositions and methods for CAR T cell therapy | CD47, PBK, GZMB | TSHR 4199/4885HTT 2544/4885F2 4114/4885 |
| US-11779602-B2 | Methods of use for CAR T cells | CD47, CD4, CD2 | TSHR 3587/4885HTT 2770/4885F2 3224/4885 |
| US-20100104626-A1 | METHODS AND COMPOSITIONS FOR TREATING AND DIAGNOSING KIDNEY DISEASE | VDR, GC, CYP24A1 | TSHR 428/4885HTT 4372/4885F2 372/4885 |
| US-20120065149-A1 | Vitamin receptor binding drug delivery conjugates | VDR, CYP2R1, CYP24A1 | TSHR 377/4885HTT 4087/4885F2 1983/4885 |
| US-20120270791-A1 | Methods and Compositions for Treating and Diagnosing Kidney Disease | VDR, GC, CYP24A1 | TSHR 428/4885HTT 4372/4885F2 372/4885 |
| US-11795195-B2 | Antibody-drug conjugates including hemiasterlin derivative | HSD3B2, HSD3B1, HSD11B2 | TSHR 1852/4885HTT 1233/4885F2 2542/4885 |
| US-20080280937-A1 | Ligand Conjugates of Vinca Alkaloids, Analogs, and Derivatives | VDR, HCAR1, FOLR1 | TSHR 871/4885HTT 2010/4885F2 4575/4885 |
| US-20100048490-A1 | BINDING LIGAND LINKED DRUG DELIVERY CONJUGATES OF TUBULYSINS | TEK, TEKT1, VDR | TSHR 1341/4885HTT 1841/4885F2 4467/4885 |
| US-11717514-B2 | PSMA binding ligand-linker conjugates and methods for using | FOLH1, KLK3, PSMA1 | TSHR 3006/4885HTT 4374/4885F2 2448/4885 |
| US-12018093-B2 | Hemiasterlin derivatives and antibody-drug conjugates including same | FCGRT, QARS1, INHA | TSHR 1863/4885HTT 359/4885F2 2977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.